Naringin enhances reverse cholesterol transport in high fat/low streptozocin induced diabetic rats
No Thumbnail Available
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Description
Naringin, a citrus-derived flavonoid with antihyperglycemic, antihyperlipidemic, and antioxidant properties, is
reported to be a useful nutraceutical in the management of diabetes and its complications. This study investigated
the mechanism of antiatherogenic properties of naringin in type 2 diabetes (T2DM) using high fat-low
streptozocin rat model of T2DM. Rats were treated daily with 50, 100 and 200 mg/kg naringin orally for 21days.
Levels of biomarkers of T2DM, lipid profile and activity of paraoxonase (PON) were assayed spectrophotometrically.
The levels of expression of hepatic 3-hydroxy-3-methyl-glutaryl-CoA reductase (Hmgcr), scavenger
receptor class B member 1 (Scarb1), aryl hydrocarbon receptor (Ahr), hepatic Lipase (Lipc), and lecithincholesterol
acyltransferase (Lcat) were assessed using relative reverse transcriptase polymerase chain reaction
technique. Naringin treatment resulted in a dose-dependent significant (p < 0.05) decrease in the levels of
plasma cholesterol and triglyceride from 84.84 ± 1.62 to 55.59 ± 1.50 mg/dL and 123.03 ± 15.11 to
55.00 ± 0.86 mg/dL, respectively, at 200 mg/kg naringin. In the liver, Scarb1 and Ahr were significantly
(p < 0.05) upregulated at 200 mg/kg naringin while Lipc and Lcat were significantly (p < 0.05) upregulated by
50 mg/kg naringin. T2DM-induced decrease in PON activities in the plasma, liver and HDL was significantly
(p < 0.05) reversed by 200 mg/kg naringin treatment. These genes play critical roles in reverse cholesterol
transport and hence our results showed that the antiatherogenic property of naringin in T2DM involves enhancement
of reverse cholesterol transport and PON activity.
Keywords
QH Natural history, QH301 Biology